Group 2H: Triple Negative Breast Cancer; Clinical Trials; Predictive Biomarkers

Poster #PO1-19-07: A phase I study accessing immunotherapy combination of balstilimab and ivermectin in patients with metastatic triple negative breast cancer

Poster #PO2-15-08: Exploring essential immune genes linked to pathological complete response and survival in early-stage triple-negative breast cancer (TNBC) after chemotherapy treatment.